RESUMO
INTRODUCTION AND OBJECTIVE: Sexually transmitted infections of the rectum and anus (STI-RA) mainly affect men who have sex with men (MSM). The incidence of STI-RA among them has increased in recent years. MATERIAL AND METHODS: Retrospective study in patients with diagnoses of STI-RA in an STI unit during the years 2014 and 2015. Epidemiological, clinical and microbiological data were collected. RESULTS: We included 95 patients, all of whom were MSM; 88.42% were HIV+; 67.17% did not use a condom during their most recent sexual intercourse; 17.91% had had sex with sex workers and 72.22% had used drugs during sexual intercourse during the previous year. A percentage of 32.92 reported symptoms that had lasted longer than 30 days. Lymphogranuloma venereum (LGV) was diagnosed in 54.73% of the patients. All patients who presented with proctitis and perianal ulcers were diagnosed with LGV infection. All those who presented perianal ulcers without proctitis were diagnosed with syphilis. CONCLUSIONS: All the patients affected by STI-RA were MSM, most of them HIV+, had engaged in high-risk sexual behaviour and had suffered prolonged symptomatology. Clinical and microbiological characteristics of STI-AR could help adjust the empiric therapy.
Assuntos
Doenças do Ânus/epidemiologia , Doenças Retais/epidemiologia , Infecções Sexualmente Transmissíveis/epidemiologia , Sexo sem Proteção , Adulto , Idoso , Doenças do Ânus/etiologia , Doenças do Ânus/virologia , Bissexualidade , Coinfecção/epidemiologia , Comorbidade , Preservativos/estatística & dados numéricos , Infecções por HIV/epidemiologia , Homossexualidade Masculina , Humanos , Drogas Ilícitas , Incidência , Linfogranuloma Venéreo/epidemiologia , Linfogranuloma Venéreo/transmissão , Linfogranuloma Venéreo/virologia , Masculino , Pessoa de Meia-Idade , Proctite/epidemiologia , Proctite/etiologia , Doenças Retais/etiologia , Doenças Retais/virologia , Estudos Retrospectivos , Infecções Sexualmente Transmissíveis/etiologia , Infecções Sexualmente Transmissíveis/virologia , Espanha/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Sífilis/epidemiologia , Sífilis/etiologia , Sífilis/transmissão , Viagem , Adulto JovemAssuntos
Fármacos Anti-HIV/uso terapêutico , Darunavir/uso terapêutico , Substituição de Medicamentos , Infecções por HIV/tratamento farmacológico , Cobicistat/uso terapêutico , Combinação de Medicamentos , Farmacorresistência Viral , Quimioterapia Combinada , Humanos , Ritonavir/uso terapêutico , Carga ViralRESUMO
INTRODUCTION: Dolutegravir is the first second-generation integrase inhibitor approved for the treatment of naïve as well as experienced HIV-infected individuals. AREAS COVERED: Data from pharmacokinetics, efficacy, safety, tolerability and resistance are reviewed from in vitro studies, Phase II and III clinical trials published in PubMed (Dolutegravir; S/GSK1349572) or presented in international meetings. EXPERT OPINION: Data from studies and clinical trials indicate that dolutegravir is safe, well tolerated and highly efficacious in the treatment of both antiretroviral-naïve and treatment-experienced patients and appears to have a higher genetic barrier to resistance than first-generation integrase inhibitors.